CompletedPhase 1

Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects

18 participantsStarted 2009-09

Plain-language summary

THVD-201 is a novel combination of a muscarinic antagonist (tolterodine) and a muscarinic agonist (pilocarpine).

Who can participate

Age range18 Years – 45 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy males, 18 - 45 years of age. * BMI 20-30 m2. Exclusion Criteria: * Subjects who have a history of sensitivity to antimuscarinic or muscarinic agents or related derivatives. * Clinically significant ECG, vital signs and clinical laboratory indices.

What they're measuring

Reductions in stimulated salivary flow (SSF)

Timeframe: From Baseline

Trial details

NCT IDNCT01036035

SponsorTheraVida, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-03

View on ClinicalTrials.gov More Incontinence trials